The ARFGAP1 Knockout Jurkat Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population featuring targeted disruption of the ARFGAP1 gene. This loss-of-function model is generated in Jurkat T lymphoblast cells and provides a renewable, pooled cellular resource for investigating ARFGAP1-dependent processes. The polyclonal format preserves genetic heterogeneity that may approximate physiological diversity while removing functional ARFGAP1 protein expression, enabling robust studies of ER?Golgi retrograde transport and COPI vesicle dynamics without the need for single-cell clonal isolation.
Jurkat cells are an immortalized T lymphocyte line originally derived from the peripheral blood of a 14-year-old male with T cell acute lymphoblastic leukemia. Widely employed as a model system for T cell receptor signaling, activation, and apoptosis, Jurkat cells also serve as a platform for studying membrane trafficking in a cancer-relevant context. Their rapid growth, suspension culture characteristics, and well-characterized signaling networks make them highly amenable to genetic manipulation and functional assays examining secretory pathway regulation under leukemic conditions.
ARFGAP1 functions as a GTPase-activating protein that specifically stimulates the hydrolysis of GTP bound to ARF1, thereby converting ARF1 to its inactive GDP-bound state. This catalytic activity is integral to COPI coat disassembly, a critical step in retrieving cargo receptors and SNARE proteins from the cis-Golgi and vesicular?tubular clusters back to the endoplasmic reticulum. Upstream, ARFGAP1 activity is regulated by ARF1-GTP, membrane curvature, and the COPI coatomer complex, with additional modulatory input from protein kinase C. Downstream, ARF1 inactivation triggers COPI dissociation, facilitates the retrograde transport of KDEL receptor-bound luminal proteins and p24 family cargo receptors, and modulates AP-1 adaptor-dependent trafficking at the trans-Golgi network. Key participants in this network include the guanine nucleotide exchange factor GBF1, which activates ARF1, and the ER?Golgi intermediate compartment marker ERGIC-53, which cycles through COPI-dependent pathways. ARFGAP1 interacts directly with ARF1, the COPI coatomer, KDEL receptor, and p24 proteins, positioning it as a central coordinator of organelle identity and secretory homeostasis.
In the Jurkat T lymphoblast background, disruption of ARFGAP1 provides a valuable tool for dissecting how Golgi architecture and retrograde trafficking influence T cell biology and leukemia pathophysiology. As a rapidly dividing cell line with active secretion and receptor recycling, Jurkat cells place high demands on the ER?Golgi interface. Loss of ARFGAP1 may perturb Golgi morphology, alter the kinetics of cargo receptor recycling, and induce compensatory changes in stress pathways, enabling researchers to probe the links between trafficking fidelity and cancer cell proliferation or drug sensitivity. Moreover, because Golgi-related disorders and oncogenic secretory adaptations are emerging themes in cancer biology, this knockout model offers a platform for identifying vulnerabilities specific to transformed T cells.
These polyclonal ARFGAP1 knockout cells are well suited for a broad range of functional experiments, including immunofluorescence microscopy to assess Golgi morphology and COPI localization, brefeldin A resistance assays to interrogate retrograde transport, secretion assays of engineered model cargo such as Gaussia luciferase or cytokine reporters, and biochemical determination of ARF1-GTP levels by pull-down or western blot. The model further supports co-immunoprecipitation studies to map ARFGAP1?ARF1?COPI interactions and retrograde transport measurements using KDEL-bearing constructs. Typical applications span vesicular trafficking research, cancer cell biology, ER stress response analysis, and drug screening for modulators of intracellular transport. For detailed product information and technical support, please contact Ascent Research.
